Early Clinical Response As A Predictor of Subsequent Response to Ixekizumab Treatment: Results from A Phase Ii Study of Patients with Moderate-To-Severe Plaque Psoriasis

B. Zhu,E. Edson-Heredia,G. S. Cameron,W. Shen,J. Erickson,D. Shrom,P. Wang,S. Banerjee,K. B. Gordon

DOI: https://doi.org/10.1111/bjd.12610

2013-01-01

Abstract:Early identification of responsiveness to biologic treatments in psoriasis has significant clinical and economic implications.

What problem does this paper attempt to address?

Efficacy and Safety of Ixekizumab in Chinese Patients with Moderate-to-Severe Plaque Psoriasis: 60-Week Results from a Phase 3 Study

Xia Li,Jie Zheng,Wei-Li Pan,Min Zheng,Yan Lu,Fu-Qiu Li,Yang-Feng Ding,Jian-Zhong Zhang,Hong-Ying Li,Wen-Long Rui

DOI: https://doi.org/10.1097/jd9.0000000000000244

2022-01-01

International Journal of Dermatology and Venereology

Abstract:Objective: Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin-17A and is approved for treating moderate-to-severe psoriasis. This phase 3, multicenter, randomized, double-blind, placebo-controlled trial (NCT03364309; registered December 6, 2017) evaluated the safety and efficacy of ixekizumab in Chinese patients with moderate-to-severe psoriasis. Methods: 438 patients were randomized 2:2:1 to 80 mg ixekizumab every 2 weeks (IXE Q2W, n = 176), 80 mg ixekizumab every 4 weeks (IXE Q4W, n = 174), or placebo (n = 88). Efficacy was assessed by evaluating the static Physician’s Global Assessment score of 0 or 1 (sPGA [0,1]) and Psoriasis Area and Severity Index (PASI) 75/90/100 responses, and nonresponder imputation was used for handling missing data. The safety profile was evaluated by assessing treatment emergent adverse events (AEs) and serious AEs. Results: At week 12, the sPGA (0,1) response rates were 3.4%, 79.9%, and 86.4% in the placebo, IXE Q4W, and IXE Q2W groups, respectively. The PASI 75/90/100 response rates were 8.0%/2.3%/0.0%, 87.4%/75.9%/29.3%, and 93.8%/82.4%/33.0% in the placebo, IXE Q4W, and IXE Q2W groups, respectively. Ixekizumab led to rapid PASI 50 responses, as early as week 1, whereas PASI 75 and sPGA (0,1) responses were observed from week 2. sPGA (0,1) and sPGA (0) responses were maintained through week 60 in a higher proportion of patients receiving IXE Q4W vs. placebo. The safety profile was consistent with previous studies of ixekizumab in psoriasis. Conclusion: Ixekizumab showed a rapid onset of action and high efficacy that was maintained through 60 weeks and was well tolerated with no unexpected AEs, in Chinese patients with moderate-to-severe plaque psoriasis.
Pharmacokinetics, Safety, and Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 1, Single- and Multiple-Dose Study.

Min Zheng,Xiang Chen,Feng Wang,Jisu Chen,Kimberley Jackson,Fan Yang,Christopher Payne,HongYing Li,YiHui Wang,ZiPei Xiao,Jie Zheng

DOI: https://doi.org/10.1007/s12325-023-02575-1

2023-01-01

Advances in Therapy

Abstract:We evaluated the pharmacokinetics (PK), safety, and efficacy of ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, in Chinese patients with moderate-to-severe psoriasis. In this phase 1, multicenter, open-label study, adults (≥ 18 years) diagnosed with moderate-to-severe plaque psoriasis for ≥ 6 months involving ≥ 10
Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the Effisayil 1 study

A. D. Burden,Y. Okubo,M. Zheng,D. Thaci,P. van de Kerkhof,N. Hu,M. Quaresma,C. Thoma,S. E. Choon

DOI: https://doi.org/10.1111/exd.14824

2023-01-01

Experimental Dermatology

Abstract:Effisayil 1 was a multicentre, randomized, double-blind, placebo-controlled study of the anti-interleukin (IL)-36 receptor monoclonal antibody, spesolimab, in patients presenting with a generalized pustular psoriasis (GPP) flare. Previously published data from this study revealed that within 1 week, rapid pustular and skin clearance were observed in patients receiving spesolimab versus placebo. In this pre-specified subgroup analysis, the efficacy of spesolimab was evaluated according to patient demographic and clinical characteristics at baseline in patients receiving spesolimab (n = 35) or placebo (n = 18) on Day 1. Efficacy was by assessed by achievement of primary endpoint (Generalized Pustular Psoriasis Physician Global Assessment [GPPGA] pustulation subscore of 0 at Week 1) and key secondary endpoint (GPPGA total score of 0 or 1 at Week 1). Safety was assessed at Week 1. Spesolimab was found to be efficacious and had a consistent and favourable safety profile in patients presenting with a GPP flare, regardless of patient demographics and clinical characteristics at baseline.
14066 Pharmacokinetics, Safety and Efficacy of Ixekizumab in Chinese Patients with Plaque Psoriasis: Results from a Phase 1 Single- and Multiple-Dose Study

Feng Wang,Min Zheng,Xiang Chen,Chen Jisu,Kimberley Jackson,Fan Emily Yang,Christopher Payne,Jie Zheng

DOI: https://doi.org/10.1016/j.jaad.2020.06.606

IF: 15.487

2020-01-01

Journal of the American Academy of Dermatology

Abstract:Objective: To investigate the pharmacokinetics (PK), safety and efficacy of ixekizumab after single and multiple subcutaneous (SC) doses in Chinese patients with moderate to severe plaque psoriasis.
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

Andrew Blauvelt,Kim A Papp,Christopher E M Griffiths,Luis Puig,Jamie Weisman,Yves Dutronc,Lisa Farmer Kerr,Dapo Ilo,Lotus Mallbris,Matthias Augustin

DOI: https://doi.org/10.1007/s40257-016-0246-9

Abstract:Background: Patients with psoriasis who have an inadequate response to one biologic may benefit from switching to a new biologic, such as ixekizumab, a high affinity monoclonal antibody that selectively targets interleukin (IL)-17A. Objective: Our aim was to assess the response to ixekizumab in patients with moderate-to-severe plaque psoriasis who did not respond adequately to etanercept using a post-hoc analysis in two phase III studies. Methods: For the subanalyses in two phase III trials (UNCOVER-2 and -3), non-response was defined by either failure to have a static physician global assessment (sPGA) of 0/1 in UNCOVER-2 or failure to have at least 75% improvement in psoriasis area and severity index (PASI 75) in UNCOVER-3 at Week 12 of each study. Non-responders treated with twice-weekly etanercept 50 mg in the first 12 weeks received two injections of placebo at Week 12 (4-week wash-out period), followed by ixekizumab every 4 weeks (Q4W) for Weeks 16-60. Non-responders to placebo in the first 12 weeks were administered ixekizumab 160 mg at Week 12, followed by ixekizumab Q4W for Weeks 16-60. Results: After switching to ixekizumab Q4W, a substantial proportion of patients with moderate-to-severe psoriasis who did not respond to etanercept experienced rapid and durable improvement in all efficacy evaluations. Among sPGA 0/1 (UNCOVER-2) and PASI 75 (UNCOVER-3) non-responders to etanercept, 73.0% achieved sPGA 0/1 and 78.2% achieved PASI 75, respectively, after 12 weeks of ixekizumab treatment. Safety profiles in patients switched from etanercept to ixekizumab were similar to those in patients switched from placebo to ixekizumab. Conclusion: Patients who were non-responders to etanercept after 12 weeks, as defined by failure to meet sPGA 0/1 (UNCOVER-2) or PASI 75 (UNCOVER-3), achieved high levels of response 12 weeks after switching to ixekizumab. Studies are registered with ClinicalTrials.gov (NCT01597245 and NCT01646177).
Efficacy and Safety Analysis in Chinese Patients with Moderate-to-Severe Psoriasis from a Phase 3 Trial: Impact of Treatment Withdrawal and Retreatment of Ixekizumab

Xinghua Gao,Weili Pan,Min Zheng,Fuqiu Li,Xiuqin Dong,Dong Lv,Zaipei Guo,Jinnan Li,Xuan Wang,Songmei Geng

DOI: https://doi.org/10.1007/s12325-024-03030-5

2024-01-01

Advances in Therapy

Abstract:In China, approximately 2.3 million people have psoriasis. Continuous treatment is recommended for moderate-to-severe psoriasis. This study aimed to evaluate the outcomes of continuous versus interrupted ixekizumab (IXE) treatment and retreatment with IXE after disease worsening in Chinese patients. In this Phase 3, multicenter, randomized, double-blind, placebo-controlled study, patients were randomized to IXE or placebo at Week 0. At Week 12, IXE responders (static Physician’s Global Assessment [sPGA] score, 0 or 1 [0,1]) were re-randomized (2:1) to IXE (IXE/IXE, continuous treatment) or placebo (IXE/PBO, interrupted treatment). After re-randomization, treatment in IXE/PBO patients with disease worsening (relapse, sPGA ≥ 3) was switched to IXE every 4 weeks (IXE/PBO + IXEQ4W, retreatment). Efficacy was assessed by evaluating the response rates of Psoriasis Area and Severity Index (PASI) 75/90/100, sPGA (0,1), Dermatology Life Quality Index (DLQI) (0,1), mean PASI, and Itch Numerical Rating Scale (NRS) scores and improvements of special body areas. Safety was evaluated by assessing treatment-emergent adverse events (AEs) and serious AEs. At Week 12, 289 IXE responders were re-randomized to the IXE/IXE group (192 patients) and IXE/PBO group (97 patients). High rates of PASI 75 and sPGA (0, 1) responses were maintained in the IXE/IXE group until Week 60. At Week 60, 88 (90.7
Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials

Alexander Egeberg,Curdin Conrad,Patricia Gorecki,Sven Wegner,Jozefien Buyze,Lorenzo Acciarri,Diamant Thaçi

DOI: https://doi.org/10.1007/s13555-024-01123-1

2024-03-16

Dermatology and Therapy

Abstract:This study aimed to understand treatment response dynamics, including factors associated with favorable response, among patients with moderate-to-severe psoriasis who received guselkumab, adalimumab, or secukinumab.

dermatology
25258 Efficacy and Safety of Ixekizumab in Chinese Patients with Moderate-to-severe Plaque Psoriasis: 12-Week Results from a Phase 3 Study

Wenlong Rui,Xia Li,Jie Zheng,Weili Pan,Min Zheng,Yan Lu,Fuqiu Li,Yangfeng Ding,Jianzhong Zhang,Hongying Li

DOI: https://doi.org/10.1016/j.jaad.2021.06.246

IF: 15.487

2021-01-01

Journal of the American Academy of Dermatology

Abstract:Background: Ixekizumab is a high-affinity monoclonal antibody that selectively targets IL-17A.
Early clinical response associates with long-term outcomes with ixekizumab in radiographic axial spondyloarthritis

Sofia Ramiro,Cédric Lukas,Louis Bessette,Pendleton Wickersham,Tommaso Panni,Rebecca Bolce,Soyi Liu-Leage,Boris Janos,Michael J Nissen,James Cheng-Chung Wei

DOI: https://doi.org/10.1136/rmdopen-2024-004429

2024-07-15

RMD Open

Abstract:Background The Assessment of SpondyloArthritis international Society-European Alliance of Associations for Rheumatology recommendations for axial spondyloarthritis (axSpA) management include patient assessment for biological disease-modifying antirheumatic drug (bDMARD) treatment response after at least 12 weeks of treatment. The current treat-to-target strategy for axSpA is to achieve inactive disease (ID; Axial Spondyloarthritis Disease Activity Score (ASDAS) <1.3) or at least low disease activity (LDA; 1.3≤ASDAS<2.1). To investigate the association between treatment response at week 12 and/or week 24 and attainment of the ASDAS<2.1 treat-to-target recommendation at week 52 in bDMARD-naïve patients with radiographic (r-)axSpA treated with ixekizumab (IXE). Methods This post hoc analysis included patients randomly assigned to IXE 80 mg every 4 weeks from COAST-V (NCT02696785), a phase 3 trial in bDMARD-naïve patients with r-axSpA. The proportion of patients who achieved ASDAS<2.1 at week 52 was measured among those who attained or not clinically important improvement (CII, ASDAS≥1.1) response, and among those with ID, LDA and high or very high disease activity at week 12 and/or week 24. Non-response was assumed for missing data. Results Amongst 81 patients, 47 (58.0%) achieved ASDAS CII at week 12, with 70.2% (n=33) achieving ASDAS<2.1 at week 52. At week 24, 52 (64.2%) patients achieved ASDAS CII, with 71.2% (n=37) achieving ASDAS<2.1 at week 52. Of the 24 patients who did not achieve ASDAS CII at either week 12 or week 24, 5 (20.8%) achieved ASDAS<2.1 at week 52. Conclusion This analysis reinforces the current recommendation that continuing treatment in those achieving ASDAS CII at week 12 and/or week 24 increases the likelihood of obtaining ID/LDA at week 52. Trial registration number NCT02696785.

rheumatology
Study Protocol of the Global Effisayil 1 Phase II, Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial of Spesolimab in Patients with Generalized Pustular Psoriasis Presenting with an Acute Flare

Siew Eng Choon,Mark G. Lebwohl,Slaheddine Marrakchi,A. David Burden,Tsen-Fang Tsai,Akimichi Morita,Alexander A. Navarini,Min Zheng,Jinhua Xu,Hamida Turki,Sushmita Rajeswari,Hongjie Deng,Kay Tetzlaff,Christian Thoma,Herve Bachelez

DOI: https://doi.org/10.1136/bmjopen-2020-043666

IF: 3.006

2021-01-01

BMJ Open

Abstract:Introduction Generalized pustular psoriasis (GPP) is a rare, potentially life-threatening disease characterised by recurrent flares of widespread neutrophilic aseptic skin pustular eruption. Despite the availability of approved biologics for GPP in Japan, Taiwan and Thailand, associated evidence is largely based on uncontrolled studies in which acute flares were not directly assessed. Therefore, there is a high unmet need to investigate new rapid-acting effective treatments that resolve symptoms associated with acute GPP flares. A prior Phase I proof-of-concept study showed rapid improvements in skin and pustule clearance with a single intravenous dose of spesolimab, a novel anti-interleukin-36 receptor antibody, in patients presenting with an acute GPP flare. Here, we present the design and rationale of Effisayil 1, a global, Phase II, placebo-controlled study to evaluate the efficacy, safety and tolerability of spesolimab in patients presenting with an acute GPP flare.Methods and analysis At least 51 patients with an acute GPP flare will be randomised 2:1 to receive a single 900 mg intravenous dose of spesolimab or placebo and followed for up to 28 weeks. The primary endpoint is a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of 0 (pustule clearance) at Week 1. The key secondary endpoint is a GPPGA score of 0 or 1 (clear or almost clear) at Week 1. Safety will be assessed over the study duration by the occurrence of treatment-emergent adverse events. Blood and skin biopsies will be collected to assess biomarkers. Superiority of spesolimab over placebo in the proportion of patients achieving the primary and key secondary endpoints will be evaluated.Ethics and dissemination The study complies with the ethical principles of the Declaration of Helsinki, the International Council for Harmonisation’s Good Clinical Practice and local regulations. Ethics committee approvals have been obtained for each centre from all participating countries and are listed in online supplementary file 1. Primary results will be published in a peer-reviewed journal.Trial registration details ClinicalTrials.gov identifier: NCT03782792; Pre-results.
[Effects of three Chinese traditional drugs on afferent discharge from single muscle spindle in toads].

Yunfang Gao,Xiao‐li Fan

2005-02-01

Abstract:OBJECTIVE To shed some light on treatment of muscle atrophy through testing the effects of several Chinese traditional drugs that can invigorate blood circulation on the afferent discharge of muscle spindle. METHOD Single muscle spindle was isolated from sartorius muscle of toad. Afferent discharge from the muscle spindle was recorded using air-gap technique and effects of three Chinese traditional drugs on afferent activity of the muscle spindle were observed. RESULT Ligustrazine could markedly tingle the spontaneous electrical activity of the muscle spindle, and it also showed a good dose-response relationship, while Salvia Miltiorrhiza and Safflower had no such excitative effect. CONCLUSION It is known that ligustrazine can expand blood vessels and agitate microcirculation, and this effect on the muscle spindle makes it helpful for persons with muscle atrophy.
Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)

Gooderham, Melinda

DOI: https://doi.org/10.1007/s13555-023-01075-y

2024-02-10

Dermatology and Therapy

Abstract:When assessing the effect of a therapy for psoriasis (PsO), it is important to consider speed of response and cumulative response. However, responses among biologics may differ by body regions. This post hoc analysis compares speed of response and cumulative response for ixekizumab (IXE), an interleukin-17A antagonist, and guselkumab (GUS), an interleukin-23p19 inhibitor, in different body regions of patients with moderate-to-severe plaque PsO participating in the IXORA-R study, up to week 24.

dermatology
Ixekizumab treatment in patients with moderate-to-severe plaque psoriasis in a real-world clinical setting

Neslihan Demirel Öğüt,Sema Koç Yıldırım,Ece Erbağcı,Fatma Aslı Hapa

DOI: https://doi.org/10.1111/jocd.15217

Abstract:Background: The efficacy and safety reports of ixekizumab for moderate-to-severe plaque psoriasis may vary between clinical trials and real-world studies. Aim: To analyze the real-world data of ixekizumab therapy to evaluate its efficacy and safety and highlight the factors influencing the treatment response in the real-world scenario. Patients/methods: Data of 82 adult patients with moderate-to-severe chronic plaque psoriasis are included in this study. Psoriasis area severity index (PASI) 75/90/100 responses at 4, 16, 24, and 48 weeks were analyzed retrospectively from patient charts by examining demographic and clinical characteristics of the patients, especially their previous biologic experience, obesity, and involvement of hard-to-treat areas. Results: PASI75, PASI90, and PASI100 responses were achieved in 92.4%, 86.1%, and 26.6% patients at week 16 and maintained till week 48 in 92.3%, 86.5%, and 17.3% patients. PASI90 responses in obese patients were significantly lower than non-obese patients at week 4 (33.3% vs. 69.6%, p = 0.042), but this difference was minimized by week 16 (82.4% vs. 90%, p = 0.405). PASI90 responses in biologic-naive patients were significantly higher than biologic-experienced patients at week 16 (p = 0.015). Involvement of hard-to-treat areas was negatively associated with PASI90 responses at week 16 (OR: 1591805.842; 95% CI: 1.223-2071404486740.201; p = 0.047). Conclusion: Ixekizumab provides an effective and safe biologic treatment option to patients with moderate-to-severe plaque psoriasis. Obesity, though it affects the early treatment response (till week 4), does not upset the overall treatment response beyond week 16. Previous biologic exposure and involvement of hard-to-treat areas are important prognostic factors for achieving high PASI responses in psoriatic patients.
Mechanisms in residual plaques in patients with an overall good response to biologics

K. M. Smith,S. Mashiko,R. Edelmayer,Y. Bi,V. Kaimal,L. Olson,S. Huang,J. Wetter,K. Salte,J. Wang,X. Li,S. Garcet,A. Kannan,S. Cao,C. Maari,E. St-Cyr Proulx,Z. Liu,J. Krueger,M. Sarfati,R. Bissonnette

DOI: https://doi.org/10.1016/j.jid.2018.03.491

IF: 7.59

2018-01-01

Journal of Investigative Dermatology

Abstract:The majority of psoriasis patients treated with biologics respond with 75-90% skin clearance. These patients possess “residual plaques” which can cover 1-5% of body surface area. To elucidate mechanisms of plaque persistence despite overall good response to drug, we studied fifty subjects: psoriasis patients treated with three different biologics with refractory plaques, untreated patients, and healthy controls. All subjects had skin biopsies collected. Biopsies were characterized using three methods: mRNA gene expression, histology, and FACS of isolated hematopoietic cells. Gene expression analysis revealed persistence of key psoriasis pathways in residual plaques, in spite of evidence of drug effects. Active pathways include “Granulocyte Adhesion and Diapedesis”, “Role of IL-17A in Psoriasis”, and “Interferon Signaling”. All data types showed some dampening of immune mediators by biologic therapy. Focal decreases in parakeratosis and keratinocyte proliferation in treated plaques consistent with a partial drug effect were observed histologically. Single cell analysis showed differential reduction in IL-17 producing CD103- T cells and increase in mast cells producing IL-22 while frequency of CD103+ T cells remained unchanged, providing further evidence of drug effect. Our hypothesis is that high inflammatory burden persists in refractory plaques and standard doses of therapy are inadequate to induce clinical resolution.
Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies

April Armstrong,Alvaro González-Cantero,Saakshi Khattri,Guilherme Muzy,William N. Malatestinic,Anastasia Lampropoulou,Meghan Feely,Sophia Kyoungah See,Can Mert,Andrew Blauvelt

DOI: https://doi.org/10.1007/s13555-024-01136-w

2024-03-25

Dermatology and Therapy

Abstract:The National Psoriasis Foundation (NPF) recommends evaluating patient response to treatment at week 12, with a target response of ≤ 1% body surface area (BSA) affected by plaque psoriasis and an acceptable response of BSA ≤ 3% or ≥ 75% improvement. This post hoc analysis compared the achievement of NPF target and acceptable responses for ixekizumab (IXE) versus other biologics.

dermatology
Early Improvements with Guselkumab Associate with Sustained Control of Psoriatic Arthritis: Post hoc Analyses of Two Phase 3 Trials

Jeffrey R Curtis,Atul Deodhar,Enrique R Soriano,Emmanouil Rampakakis,May Shawi,Natalie J Shiff,Chenglong Han,William Tillett,Dafna D Gladman

DOI: https://doi.org/10.1007/s40744-024-00702-0

Abstract:Introduction: Patterns of treatment response can inform clinical decision-making. This study assessed the course and impact of achieving minimal clinically important improvement (MCII) in clinical measures and patient-reported outcomes (PROs) with guselkumab in patients with active psoriatic arthritis (PsA). Methods: Post hoc analyses evaluated 1120 patients with PsA receiving guselkumab every 4 or 8 weeks (Q4W/Q8W) or placebo from DISCOVER-1 (31% tumor necrosis factor inhibitor-experienced) and DISCOVER-2 (biologic-naïve). Achievement of MCII in clinical Disease Activity Index for PsA (cDAPSA), patient global assessment (PtGA) of arthritis, PtGA of psoriasis, patient-reported pain, Functional Assessment of Chronic Illness Therapy-Fatigue, Health Assessment Questionnaire-Disability Index, 36-item Short-Form Health Survey Physical Component Summary score, PtGA Arthritis + Psoriasis, and PsA Disease Activity Score (PASDAS) was compared between the guselkumab and placebo groups using Cox regression. Logistic regression adjusting for baseline factors evaluated associations between early (W4/W8) MCII achievement and stringent response (≥%50/%70 improvement in American College of Rheumatology response criteria, cDAPSA low disease activity [LDA], PASDAS LDA, and minimal disease activity) at W24/W52 among guselkumab-randomized patients. Results: Among patients with highly active PsA (baseline cDAPSA = 44.1-45.0, PASDAS = 6.4-6.5), times to MCII were significantly faster for guselkumab vs. placebo (hazard ratios 1.3-2.5; P < 0.05). Across measures, at first timepoint assessed, MCII rates were significantly higher with guselkumab (Q4W/Q8W 28-68%/29-65%) vs. placebo (19-47%; both P < 0.05). Early (W4/W8) MCII with guselkumab associated with higher odds of achieving stringent responses at W24/W52 (odds ratios 1.4-17.2/1.4-5.4). Conclusions: In a mixed PsA population, significant proportions of patients treated with guselkumab achieved early (W4/W8) MCII across clinical and PRO measures, which associated with a higher likelihood of attaining clinically relevant improvements and low levels of disease activity at W24/W52. Trial registration: DISCOVER-1 (NCT03162796). DISCOVER-2 (NCT03158285).
Higher rates of skin clearance and efficacy in challenging body areas are associated with better health-related quality of life following ixekizumab maintenance treatment in pediatric patients with plaque psoriasis

Adelaide A Hebert,Margaret A Bobonich,Claudia Rodriguez Capriles,Gaia Gallo,Lingnan Li,Najwa Somani,Terri Ridenour,Yan Wang,Emily Edson-Heredia,Emily M Becker

DOI: https://doi.org/10.1111/pde.14892

Abstract:Background/objectives: Information is limited on the relationship between skin clearance, resolution of challenging body areas, and improvement of patient-reported outcomes (PROs) in pediatric psoriasis. Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, is approved for the treatment of moderate-to-severe psoriasis in patients aged 6 to <18 years. This study examines improvement in psoriasis clearance in challenging body areas in pediatric patients relative to health-related quality of life. Methods: Data from the IXORA-PEDS trial (NCT03073200) were analyzed, and changes from baseline were measured for overall Psoriasis Area and Severity Index (PASI), static Physicians' Global Assessment of psoriasis (sPGA), Psoriasis Scalp Severity Index (PSSI), Palmoplantar Psoriasis Area and Severity Index (PPASI), and Nail Psoriasis Severity Index. Rates of Dermatology Life Quality Index (DLQI), or Children's DLQI (CDLQI), scores of 0 or 1 were evaluated using the Cochran-Armitage trend test. Results: Higher rates of DLQI/CDLQI (0,1) scores were significantly associated with greater PASI and PSSI responses at both Week 12 and Week 48 (p < .0001). A significant association was also observed between DLQI/CDLQI (0,1) and sPGA scores (p < .0001). Significantly higher rates of DLQI/CDLQI (0,1) scores were achieved in patients with greater levels of palmoplantar clearance as measured by PPASI at Week 12 (p = .0139), but significance was not sustained at Week 48 (p = .0896). Conclusions: Greater skin clearance and scalp resolution are associated with better PROs over a short-term (12-week) and long-term (48-week) period. This demonstrates that greater improvement of skin clearance and scalp resolution may benefit quality of life in pediatric patients with psoriasis.
Effectiveness of Ixekizumab in Chinese Patients with Moderate-Severe Plaque Psoriasis with Special Area Involvement: Subanalysis of a Prospective, Multicenter, Observational Real-World Study

Ying Li,Chengzhi Lv,Lin Dang,Bingjiang Lin,Juan Tao,Chunlei Zhang,Xiaoyong Zhou,Han Ma,Yi Lu,Rong Chen,Jinnan Li,Guanshen Dou,Yunsheng Liang,Yanhua Liang,Yuling Shi

DOI: https://doi.org/10.1007/s13555-024-01134-y

2024-03-29

Dermatology and Therapy

Abstract:Ixekizumab, a monoclonal antibody against interleukin-17A, demonstrated effectiveness in the treatment of psoriasis in a Chinese real-world study that was consistent with previous randomized controlled trials. Here, we report further analyses from this study to explore the effectiveness of ixekizumab for treating patients with psoriasis and the involvement of special body areas (scalp, nail, joint, palmoplantar, or genital areas).

dermatology
Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry

Benjamin Lockshin,Ryan W Harrison,Robert R McLean,Margaux M Crabtree,Bruce W Konicek,Baojin Zhu,William N Malatestinic,Bilal Atiya,Mwangi J Murage,Russel T Burge

DOI: https://doi.org/10.1007/s13555-022-00834-7

Abstract:Introduction: The aim of this work is to describe real-world biologic-experienced psoriasis patients initiating ixekizumab by prior biologic therapy status and compare the effectiveness of ixekizumab between patients who previously failed secukinumab and those who failed other biologics. We hypothesized that (1) clinical outcomes and patient-reported outcomes would improve following a switch to IXE, and (2) there would be no differences in responses between patients who previously failed secukinumab and those who failed other biologics. Methods: Participants (n = 419) included adult psoriasis patients enrolled in the CorEvitas Psoriasis Registry through 9/10/20 who switched to ixekizumab after discontinuing another biologic. Patients were classified by the biologic used immediately prior to ixekizumab and reason for discontinuation: prior secukinumab failure; prior secukinumab non-failure; prior other biologic failure; and prior other biologic non-failure. Discontinuations for efficacy reasons were considered failures; all others were considered non-failures. Baseline descriptive statistics were calculated. Multivariable Poisson regression models estimated the likelihood of response of other failure relative to secukinumab failure. Results: Mean age was 51 years; 48% were women. Psoriasis disease characteristics were similar across prior biologic groups. At 6-month follow-up, disease severity improved for all who initiated ixekizumab after discontinuing another biologic. Secukinumab failure patients who switched to ixekizumab achieved BSA ≤ 1 (49%), BSA ≤ 3 (59%), PASI75 (46%), PASI ≤ 3 (64%), and IGA ≤ 1 (40%). Other failure patients achieved BSA ≤ 1 (55%), BSA ≤ 3 (72%), PASI75 (59%), PASI ≤ 3 (74%), and IGA ≤ 1 (54%). In regression modeling, we observed patients in the other biologics failure group had an increased likelihood of achieving response for BSA ≤ 3, PASI75, PASI90, PASI100, and IGA ≤ 1 compared to patients who failed secukinumab. Conclusions: These findings suggest that patients with psoriasis who switch to ixekizumab after discontinuing another biologic demonstrate improvement in disease severity after six months. Patients who discontinued biologics other than secukinumab may be more likely to respond to ixekiziumab compared to those who switched from secukinumab.
Candidate Biomarkers For Response To Treatment In Psoriatic Disease

Rachel Offenheim,Omar F Cruz-Correa,Darshini Ganatra,Dafna D Gladman

DOI: https://doi.org/10.3899/jrheum.2024-0396

2024-09-01

Abstract:Objective: To determine whether biologic therapy alters serum CXCL10, MMP3, S100A8, ACP5, and CCL2 levels in psoriatic arthritis (PsA) and psoriasis (PsC) patients, and whether baseline levels of these proteins predict response to treatment for PsA. Methods: We included PsA patients on TNF inhibitors (TNFi), Interleukin-17 inhibitors (IL-17i), methotrexate (MTX), and untreated with bDMARDs or csDMARDs (untreated) and PsC patients on bDMARDs and matched untreated. Serum samples at baseline and 3-6 months follow-up were retrieved from the biobank. Protein levels were quantified using a Luminex multiplex assay. We compared follow-up vs baseline protein levels within groups and change in levels between groups. For the predictive potential of the biomarkers, we developed logistic regression classification models. Response to treatment was defined as: 1. Achieving low disease activity or remission (according to DAPSA), 2. 75% reduction in PASI, and 3. 50% reduction in actively inflamed joint count. Results: In PsA, TNFi reduced serum levels of all five proteins, IL-17i increased ACP5 and CCL2, and MTX reduced MMP3. Changes in MMP3 and S100A8 levels were significantly different between untreated PsA and matched biologic-treated PsA (p<0.05). There were no significant differences between treated or untreated PsC patients. Baseline levels of CXCL10, MMP3, S100A8, and ACP5 had good predictive value (AUC>0.8) for response to biologics in PsA patients. Conclusion: Biologics treatment and MTX affect serum CXCL10, MMP3, S100A8, ACP5, and CCL2 levels in PsA patients. MMP3, S100A8, ACP5, and CXCL10 have potential use as serum biomarkers to predict response to treatment for PsA.

Early Clinical Response As A Predictor of Subsequent Response to Ixekizumab Treatment: Results from A Phase Ii Study of Patients with Moderate-To-Severe Plaque Psoriasis

Efficacy and Safety of Ixekizumab in Chinese Patients with Moderate-to-Severe Plaque Psoriasis: 60-Week Results from a Phase 3 Study

Pharmacokinetics, Safety, and Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 1, Single- and Multiple-Dose Study.

Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the Effisayil 1 study

14066 Pharmacokinetics, Safety and Efficacy of Ixekizumab in Chinese Patients with Plaque Psoriasis: Results from a Phase 1 Single- and Multiple-Dose Study

Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

Efficacy and Safety Analysis in Chinese Patients with Moderate-to-Severe Psoriasis from a Phase 3 Trial: Impact of Treatment Withdrawal and Retreatment of Ixekizumab

Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials

25258 Efficacy and Safety of Ixekizumab in Chinese Patients with Moderate-to-severe Plaque Psoriasis: 12-Week Results from a Phase 3 Study

Early clinical response associates with long-term outcomes with ixekizumab in radiographic axial spondyloarthritis

Study Protocol of the Global Effisayil 1 Phase II, Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial of Spesolimab in Patients with Generalized Pustular Psoriasis Presenting with an Acute Flare

[Effects of three Chinese traditional drugs on afferent discharge from single muscle spindle in toads].

Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)

Ixekizumab treatment in patients with moderate-to-severe plaque psoriasis in a real-world clinical setting

Mechanisms in residual plaques in patients with an overall good response to biologics

Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies

Early Improvements with Guselkumab Associate with Sustained Control of Psoriatic Arthritis: Post hoc Analyses of Two Phase 3 Trials

Higher rates of skin clearance and efficacy in challenging body areas are associated with better health-related quality of life following ixekizumab maintenance treatment in pediatric patients with plaque psoriasis

Effectiveness of Ixekizumab in Chinese Patients with Moderate-Severe Plaque Psoriasis with Special Area Involvement: Subanalysis of a Prospective, Multicenter, Observational Real-World Study

Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry

Candidate Biomarkers For Response To Treatment In Psoriatic Disease